(AXSM) Axsome Therapeutics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05464T1043

Stock:

Total Rating 39
Risk 27
Buy Signal -0.48
Biotechnology +3.6
Pharmaceuticals +4.2
Market Cap: 8,227m
Avg Trading Vol: 103M USD
ATR: 3.62%
Peers RS (IBD): 50.00
Risk 5d forecast
Volatility 43.2%
Relative Tail Risk -11.9%
Reward TTM
Sharpe Ratio 0.72
Alpha 15.78
Character TTM
Beta 0.744
Beta Downside 1.084
Drawdowns 3y
Max DD 36.45%
CAGR/Max DD 1.03

EPS (Earnings per Share)

EPS (Earnings per Share) of AXSM over the last years for every Quarter: "2021-03": -0.78, "2021-06": -0.86, "2021-09": -0.93, "2021-12": -0.9, "2022-03": -1.03, "2022-06": -1.06, "2022-09": -1.07, "2022-12": -1.41, "2023-03": -0.26, "2023-06": -1.54, "2023-09": -1.32, "2023-12": -2.08, "2024-03": -1.44, "2024-06": -1.67, "2024-09": -1.3419, "2024-12": -1.54, "2025-03": -1.2157, "2025-06": -0.97, "2025-09": -0.95, "2025-12": -0.56,
EPS CAGR: 9.37%
EPS Trend: 4.6%
Last SUE: 0.48
Qual. Beats: 0

Revenue

Revenue of AXSM over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 8.82, 2022-09: 16.846, 2022-12: 24.371528, 2023-03: 94.576, 2023-06: 46.7, 2023-09: 57.794, 2023-12: 71.53, 2024-03: 74.999, 2024-06: 87.166, 2024-09: 104.762, 2024-12: 118.766, 2025-03: 121.463, 2025-06: 150.042, 2025-09: 170.992, 2025-12: 195.999,
Rev. CAGR: 136.36%
Rev. Trend: 81.1%
Last SUE: 0.63
Qual. Beats: 0

Description: AXSM Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income: -183.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.14 > 0.02 and ΔFCF/TA 8.99 > 1.0
NWC/Revenue: 32.91% < 20% (prev 66.10%; Δ -33.19% < -1%)
CFO/TA -0.14 > 3% & CFO -93.4m > Net Income -183.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.55 > 1.5 & < 3
Outstanding Shares: last quarter (50.6m) vs 12m ago 4.30% < -2%
Gross Margin: 92.56% > 18% (prev 0.91%; Δ 9165 % > 0.5%)
Asset Turnover: 101.5% > 50% (prev 67.84%; Δ 33.64% > 0%)
Interest Coverage Ratio: -26.67 > 6 (EBITDA TTM -166.5m / Interest Expense TTM 6.56m)

Altman Z'' -8.32

A: 0.30 (Total Current Assets 589.0m - Total Current Liabilities 378.8m) / Total Assets 689.8m
B: -1.89 (Retained Earnings -1.31b / Total Assets 689.8m)
C: -0.28 (EBIT TTM -174.9m / Avg Total Assets 629.2m)
D: -2.17 (Book Value of Equity -1.31b / Total Liabilities 601.5m)
Altman-Z'' Score: -8.32 = D

Beneish M -2.83

DSRI: 0.95 (Receivables 224.5m/142.0m, Revenue 638.5m/385.7m)
GMI: 0.99 (GM 92.56% / 91.37%)
AQI: 0.85 (AQ_t 0.12 / AQ_t-1 0.14)
SGI: 1.66 (Revenue 638.5m / 385.7m)
TATA: -0.13 (NI -183.2m - CFO -93.4m) / TA 689.8m)
Beneish M-Score: -2.83 (Cap -4..+1) = A

What is the price of AXSM shares?

As of March 04, 2026, the stock is trading at USD 164.05 with a total of 584,161 shares traded.
Over the past week, the price has changed by -3.47%, over one month by -12.44%, over three months by +10.99% and over the past year by +29.02%.

Is AXSM a buy, sell or hold?

Axsome Therapeutics has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy AXSM.
  • StrongBuy: 14
  • Buy: 5
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the AXSM price?

Issuer Target Up/Down from current
Wallstreet Target Price 222.5 35.6%
Analysts Target Price 222.5 35.6%

AXSM Fundamental Data Overview February 28, 2026

P/E Forward = 370.3704
P/S = 12.8847
P/B = 81.9047
Revenue TTM = 638.5m USD
EBIT TTM = -174.9m USD
EBITDA TTM = -166.5m USD
Long Term Debt = 117.6m USD (from longTermDebt, two quarters ago)
Short Term Debt = 73.0m USD (from shortTermDebt, last quarter)
Debt = 241.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -81.6m USD (from netDebt column, last quarter)
Enterprise Value = 8.15b USD (8.23b + Debt 241.3m - CCE 322.9m)
Interest Coverage Ratio = -26.67 (Ebit TTM -174.9m / Interest Expense TTM 6.56m)
EV/FCF = -86.82x (Enterprise Value 8.15b / FCF TTM -93.8m)
FCF Yield = -1.15% (FCF TTM -93.8m / Enterprise Value 8.15b)
FCF Margin = -14.69% (FCF TTM -93.8m / Revenue TTM 638.5m)
Net Margin = -28.69% (Net Income TTM -183.2m / Revenue TTM 638.5m)
Gross Margin = 92.56% ((Revenue TTM 638.5m - Cost of Revenue TTM 47.5m) / Revenue TTM)
Gross Margin QoQ = 93.71% (prev 93.03%)
Tobins Q-Ratio = 11.81 (Enterprise Value 8.15b / Total Assets 689.8m)
Interest Expense / Debt = 0.49% (Interest Expense 1.17m / Debt 241.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -138.1m (EBIT -174.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.55 (Total Current Assets 589.0m / Total Current Liabilities 378.8m)
Debt / Equity = 2.73 (Debt 241.3m / totalStockholderEquity, last quarter 88.3m)
Debt / EBITDA = 0.49 (negative EBITDA) (Net Debt -81.6m / EBITDA -166.5m)
Debt / FCF = 0.87 (negative FCF - burning cash) (Net Debt -81.6m / FCF TTM -93.8m)
Total Stockholder Equity = 72.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.11% (Net Income -183.2m / Total Assets 689.8m)
RoE = -254.1% (Net Income TTM -183.2m / Total Stockholder Equity 72.1m)
RoCE = -92.17% (EBIT -174.9m / Capital Employed (Equity 72.1m + L.T.Debt 117.6m))
RoIC = -54.78% (negative operating profit) (NOPAT -138.1m / Invested Capital 252.2m)
WACC = 8.42% (E(8.23b)/V(8.47b) * Re(8.66%) + D(241.3m)/V(8.47b) * Rd(0.49%) * (1-Tc(0.21)))
Discount Rate = 8.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.43%
[DCF] Fair Price = unknown (Cash Flow -93.8m)
EPS Correlation: 4.61 | EPS CAGR: 9.37% | SUE: 0.48 | # QB: 0
Revenue Correlation: 81.15 | Revenue CAGR: 136.4% | SUE: 0.63 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.55 | Chg7d=-0.253 | Chg30d=-0.270 | Revisions Net=-1 | Analysts=7
EPS current Year (2026-12-31): EPS=-1.04 | Chg7d=-1.387 | Chg30d=-1.482 | Revisions Net=+0 | Growth EPS=+70.0% | Growth Revenue=+54.7%
EPS next Year (2027-12-31): EPS=5.76 | Chg7d=-0.865 | Chg30d=-1.045 | Revisions Net=-1 | Growth EPS=+652.8% | Growth Revenue=+55.2%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)

Additional Sources for AXSM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle